Literature DB >> 11490177

Neurotrophic factor S100 beta in major depression.

H J Grabe1, N Ahrens, H J Rose, C Kessler, H J Freyberger.   

Abstract

Disturbances in the serotonergic system are considered to be implicated in the pathophysiology of depressive disorders. The possible role of the neurotrophic factor S100 beta, which is suspected to regulate regeneration of serotonergic synapses, has not been investigated in depressive disorders. The S100 beta concentration in the cerebrospinal fluid was measured in 11 patients with the current diagnosis of mild or moderate depressive episodes (DSM-IV) and in 11 matched control patients. Using the t test for paired samples, the presence of a depressive episode was significantly associated with an elevation of the cerebrospinal fluid concentration of S100 beta (t = 2.6, d.f. = 10, p = 0.024). Replications of this finding in severely depressed patients are necessary to confirm the association between neurotrophic factor S100 beta and depressive disorders. Copyright 2001 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11490177     DOI: 10.1159/000054922

Source DB:  PubMed          Journal:  Neuropsychobiology        ISSN: 0302-282X            Impact factor:   2.328


  18 in total

1.  The effects of gender and numbers of depressive episodes on serum S100B levels in patients with major depression.

Authors:  Kun Yang; Guang-Rong Xie; Yi-Qiu Hu; Fu-Qiang Mao; Lin-Yan Su
Journal:  J Neural Transm (Vienna)       Date:  2008-11-04       Impact factor: 3.575

2.  Mood disorders are glial disorders: evidence from in vivo studies.

Authors:  Matthias L Schroeter; Hashim Abdul-Khaliq; Julia Sacher; Johann Steiner; Ingolf E Blasig; Karsten Mueller
Journal:  Cardiovasc Psychiatry Neurol       Date:  2010-05-27

3.  Effects of S100B on Serotonergic Plasticity and Neuroinflammation in the Hippocampus in Down Syndrome and Alzheimer's Disease: Studies in an S100B Overexpressing Mouse Model.

Authors:  Lee A Shapiro; Lynn A Bialowas-McGoey; Patricia M Whitaker-Azmitia
Journal:  Cardiovasc Psychiatry Neurol       Date:  2010-08-22

4.  The astroglial protein S100B and visually evoked event-related potentials before and after antidepressant treatment.

Authors:  Guenter Hetzel; Olaf Moeller; Stefan Evers; Andreas Erfurth; Gerald Ponath; Volker Arolt; Matthias Rothermundt
Journal:  Psychopharmacology (Berl)       Date:  2004-08-14       Impact factor: 4.530

5.  Role of p11 in cellular and behavioral effects of 5-HT4 receptor stimulation.

Authors:  Jennifer L Warner-Schmidt; Marc Flajolet; Abigail Maller; Emily Y Chen; Hongshi Qi; Per Svenningsson; Paul Greengard
Journal:  J Neurosci       Date:  2009-02-11       Impact factor: 6.167

Review 6.  Astrocyte pathology in major depressive disorder: insights from human postmortem brain tissue.

Authors:  Grazyna Rajkowska; Craig A Stockmeier
Journal:  Curr Drug Targets       Date:  2013-10       Impact factor: 3.465

Review 7.  Neuropsychiatric disorders related to interferon and interleukins treatment.

Authors:  Aye Mu Myint; Markus J Schwarz; Harry W M Steinbusch; Brian E Leonard
Journal:  Metab Brain Dis       Date:  2008-12-10       Impact factor: 3.584

8.  Increased GFAP concentrations in the cerebrospinal fluid of patients with unipolar depression.

Authors:  Ludger Tebartz van Elst; Dominique Endres; Maike Michel; Bernd L Fiebich; Hanna Kuzior; Sophie Meixensberger; Benjamin Berger; Simon Maier; Kathrin Nickel; Kimon Runge; Dominik Denzel; Benjamin Pankratz; Miriam A Schiele; Katharina Domschke
Journal:  Transl Psychiatry       Date:  2021-05-21       Impact factor: 6.222

9.  Chronic mild stress induces fluoxetine-reversible decreases in hippocampal and cerebrospinal fluid levels of the neurotrophic factor S100B and its specific receptor.

Authors:  Han Rong; Gaohua Wang; Tiebang Liu; Huiling Wang; Qirong Wan; Senghong Weng
Journal:  Int J Mol Sci       Date:  2010-12-21       Impact factor: 5.923

Review 10.  Serum S100B represents a new biomarker for mood disorders.

Authors:  Matthias L Schroeter; Julia Sacher; Johann Steiner; Peter Schoenknecht; Karsten Mueller
Journal:  Curr Drug Targets       Date:  2013-10       Impact factor: 3.465

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.